No Picture
News

Boundless Bio Announces Upcoming Presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021

SAN DIEGO–(BUSINESS WIRE)–Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced plans to present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held virtually from October 7-10, 2021. Boundless Bio, in collaboration with the Dana… Click here to view original post… […]

No Picture
News

HUYABIO Announces First Patient Treated in a Pivotal Study of HBI-8000 Combined with Opdivo® (nivolumab) in Patients with Advanced Melanoma

SAN DIEGO: SAN DIEGO, Sept. 21, 2021 /PRNewswire/ — HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, announced today the first patient treated in a pivotal trial designed to measure the safety and efficacy of HBI-8000 combined with Bristol Myers Squibb’s anti-PD-1, antibody Opdivo® (nivolumab),… Click here to view original post… […]

No Picture
News

Heron Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference

SAN DIEGO: SAN DIEGO, Sept. 21, 2021 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., Chairman and Chief Executive Officer,… Click here to view original post… […]

No Picture
News

Takeda snaps up the Japanese rights to an old Shire cast-off; Boehringer Ingelheim acquires Abexxa Biologics

A week before the FDA is set to decide on Mirum Pharmaceuticals’ lead liver disease drug — an old Shire cast-off called maralixibat — Takeda is swooping in to secure the rights in Japan. Maralixibat’s roots trace back to Lumena, which was snapped up by… Click here to view original post… […]

No Picture
News

Explora BioLabs Opens New Preclinical Vivarium in S. San Francisco, Calif.

SOUTH SAN FRANCISCO, Calif.: SOUTH SAN FRANCISCO, Calif., Sept. 21, 2021 /PRNewswire/ — Explora BioLabs, a national provider of industry-leading preclinical vivarium research space and management services based in San Diego, opened a new facility here on Sept. 20, 2021. The new vivarium, located in South San Francisco, East Side,… Click here to view original post… […]

No Picture
News

Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role

SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that, Bryan Giraudo has been appointed Chief Operating Officer, in addition to his continued role as Chief Financial Officer. Mr…. Click here to view original post… […]

No Picture
News

After selling to Genentech, the old Jecure team is back at an RNA-focused startup — and more enthusiastic than ever

When Genentech swooped in to buy NASH-focused Jecure Therapeutics back in 2018, a handful of the startup’s executives weren’t quite ready to disperse. It had been just three years since Jecure launched with a preclinical portfolio of NLRP3 inhibitors — and the takeover came sooner than anyone, including CEO… Click here to view original post… […]

No Picture
News

PYC Therapeutics Announces Upcoming Poster Presentations Highlighting Preclinical Data from its Ocular and Neurologic Development Programs at TIDES USA and OTS 2021

SAN DIEGO and PERTH, Australia: SAN DIEGO and PERTH, Australia, Sept. 21, 2021 /PRNewswire/ — PYC Therapeutics (ASX: PYC), a biotechnology company combining two complementary platform technologies (selective drug delivery and precision drug design) to develop a new generation of RNA therapeutics to change the lives of patients with inherited… Click here to view original post… […]

No Picture
News

Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies

FLORHAM PARK, N.J. and SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, and Oncternal Therapeutics, Inc. (“Oncternal”) (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced they have… Click here to view original post… […]

No Picture
News

Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies

SAN DIEGO and FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (“Oncternal”) (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, and Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, today announced they have… Click here to view original post… […]

No Picture
News

STAT+: Citing competitive concerns, European Commission seeks to intervene in Illumina’s $8 billion acquisition of Grail

The European Commission argues Illumina committed an "unprecedented" violation of its rules by moving forward with its merger with Grail while investigations were ongoing. Click here to view original post… […]

No Picture
News

Neurelis Initiates Study Of VALTOCO® (diazepam nasal spray) In Children With Seizure Clusters Aged Two To Five

SAN DIEGO: SAN DIEGO, Sept. 20, 2021 /PRNewswire/ — Neurelis, Inc. announced today that it has initiated a clinical program to investigate the use of VALTOCO® (diazepam nasal spray) in children with epilepsy aged two to five as a treatment for seizure clusters. VALTOCO is currently approved by the U.S…. Click here to view original post… […]

No Picture
News

Mirati Therapeutics Announces Long-term Survival Results from an Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Checkpoint Inhibitors

SAN DIEGO: SAN DIEGO, Sept. 20, 2021 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500. Results showed durable responses and long-term survival with sitravatinib in combination with nivolumab (OPDIVO®)1 in patients… Click here to view original post… […]

No Picture
News

Complete AAV Production System Enables Scalable Gene Therapy Workflows

CARLSBAD, Calif.: CARLSBAD, Calif., Sept. 20, 2021 /PRNewswire/ — Addressing the need to make adeno-associated virus (AAV) production more efficient and scalable, Thermo Fisher Scientific has launched the integrated Gibco AAV-MAX Helper Free AAV Production System*, a complete, optimized solution that simplifies the AAV vector production workflow. The all-in-one AAV-MAX… Click here to view original post… […]

No Picture
News

Oncolytics Biotech® Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy

SAN DIEGO and CALGARY, AB: SAN DIEGO and CALGARY, AB, Sept. 20, 2021 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced preclinical data demonstrating the synergistic immunotherapeutic effects of pelareorep combined with radiotherapy in a murine cancer model. The data were featured in a poster presentation at… Click here to view original post… […]

No Picture
News

Aristea Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO: SAN DIEGO, Sept. 20, 2021 /PRNewswire/ — Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat rare serious inflammatory diseases, today announced that James Mackay, Ph.D., President and CEO, will participate in the following investor conferences in September and October: UBS Private… Click here to view original post… […]

No Picture
News

Illumina Ventures Closes $325 Million Fund

SAN FRANCISCO–(BUSINESS WIRE)–Illumina Ventures, an independently-managed, healthcare-focused venture firm, announced today the closing of its second investment fund with total commitments of $325 million, bringing its total capital under management to $560 million. The latest fund is anchored by Illumina, Inc. (Nasdaq: ILMN), with the majority of the total committed… Click here to view original post… […]

No Picture
News

Mirati Therapeutics Appoints David Meek as Chief Executive Officer

SAN DIEGO: SAN DIEGO, Sept. 20, 2021 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of David Meek as Chief Executive Officer (CEO), effective immediately. Mr. Meek will also join the Company’s Board of Directors. Charles M. Baum, M.D., Ph.D. will continue… Click here to view original post… […]

No Picture
News

Sorrento Announces an Independent Real-World Study That Reports Superior Sensitivity Results in Detecting COVID-19 Virus Infections in All-Comer General Population by COVISTIX as Compared to a Globally Leading Rapid Antigen Test

SAN DIEGO, Sept. 19, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19, today announced impressive results from an independent study conducted under real-world field conditions by INMEGEN… Click here to view original post… […]

No Picture
News

Epic Sciences Comprehensive Cancer Profiling Platform Shows Compelling Value Of Cell Analysis In Data Presented At ESMO Congress 2021

SAN DIEGO: SAN DIEGO, Sept. 18, 2021 /PRNewswire/ — Epic Sciences, Inc.’s (Epic) Comprehensive Cancer Profiling™ Platform continues to deliver compelling cell analysis information in clinical trials as data being presented today at the virtual European Society for Medical Oncology Congress 2021 (ESMO 2021) demonstrate. Data from abstract 577O –… Click here to view original post… […]